Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Van Laar, Ryan K ^a  

^a ChipDX LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NAVELBINE; DRUG DERIVATIVE; VINBLASTINE;

ACCURACY; ADULT; AGED; ALGORITHM; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CLINICAL OBSERVATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE INTERACTION; GENETIC ASSOCIATION; GENOME ANALYSIS; HIGH RISK PATIENT; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MET GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPSB3 GENE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VALIDATION PROCESS; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GENETICS; GENOMICS; HUMAN GENOME; LUNG; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; GENE EXPRESSION PROFILING; GENOME, HUMAN; GENOMICS; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 84863085860     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-30     Document Type: Article

References (31)

1. World Health Organization, Cancer Fact Sheet N°297 http://www.who.int/mediacentre/factsheets/fs297/en/index.html 21879340
2. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H, Ann Thorac Cardiovasc Surg. 2007 13 2 73 7 17505412
3. Gene expression based prognostic signatures in lung cancer: ready for clinical use? Subramanian J, Simon R, J Natl Cancer Inst 2010 102 7 464 474 10.1093/jnci/djq025 20233996
4. What should physicians look for in evaluating prognostic gene-expression signatures? Subramanian J, Simon R, Nat Rev Clin Oncol 2010 7 6 327 334 http://www.nature.com/nrclinonc/journal/v7/n6/full/nrclinonc.2010.60.html 10.1038/nrclinonc.2010.60 20421890
5. Vinorelbine plus Cisplatin vs Observation in Resected Non-Small-Cell Lung Cancer. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, et al. N Engl J Med 2005 352 25 2589 2597 10.1056/NEJMoa043623 15972865 (Pubitemid 41007845)
6. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small-Cell Lung Cancer Guideline. Pisters KMW, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, et al. J Clin Oncol 2007 25 34 5506 5518 10.1200/JCO.2007.14.1226 17954710 (Pubitemid 350232227)
7. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Pignon J-P, Tribodet H, Scagliotti GV, Douillard J-Y, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, et al. J Clin Oncol 2008 26 21 3552 3559 10.1200/JCO.2007.13.9030 18506026
8. Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer. Zhu C-Q, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et al. J Clin Oncol 2010 28 29 4417 4424 10.1200/JCO.2009.26.4325 20823422
9. Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Simon R, J Clin Oncol 2005 23 29 7332 7341 10.1200/JCO.2005.02.8712 16145063 (Pubitemid 46202346)
10. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Shedden K, Taylor JMG, Enkemann SA, Tsao M-S, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al. Nat Med 2008 14 8 822 827 10.1038/nm.1790 18641660
11. Expression Profile-Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T, J Clin Oncol 2006 24 11 1679 1688 10.1200/JCO.2005.03. 8224 16549822 (Pubitemid 46622139)
12. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Bild A, Yao G, Chang J, Wang Q, Potti, Chasse D, Joshi M, Harpole D, Lancaster J, Berchuck A, et al. Nature 2006 439 7074 353 357 10.1038/nature04296 16273092 (Pubitemid 43128862)
13. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, et al. Proc Natl Acad Sci U S A 2001 98 24 13790 13795 10.1073/pnas.191502998 11707567 (Pubitemid 33115977)
14. Semi-supervised methods to predict patient survival from gene expression data. Bair E, Tibshirani R, PLoS Biol 2004 2 4 108 10.1371/journal.pbio.0020108 15094809 (Pubitemid 39234509)
15. An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. Van Laar RK, Br J Cancer 2010 103 12 1852 1857 10.1038/sj.bjc.6605970 21119668
16. Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival. Van Laar RK, The Journal of molecular diagnostics: JMD 2011 13 3 297 304 10.1016/j.jmoldx.2010. 12.003 21458382
17. Analysis of Gene Expression Data Using BRB-Array Tools. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y, Cancer Inform 2007 3 11 17 19455231 (Pubitemid 47075796)
18. Regression models and life-tables (with discussion). Cox DR, J R Stat Soc 1972 B 34 187 220
19. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Tibshirani R, Hastie T, Narasimhan B, Chu G, Proc Natl Acad Sci 2002 99 10 6567 6572 10.1073/pnas.082099299 12011421 (Pubitemid 34526173)
20. Bioconductor: open software development for computational biology and bioinformatics. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Genome Biol 2004 5 10 80 10.1186/gb-2004-5-10-r80 15461798
21. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA, Genome Biol 2003 4 5 3 10.1186/gb-2003-4-5-p3
22. Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Li C, Fan S, Owonikoko TK, Khuri FR, Sun SY, Li R, Oncogene 2011 30 35 3802 3812 10.1038/onc.2011.94 21478903
23. Pharmacokinetics of vinorelbine in patients with liver metastases. Robieux I, Sorio R, Borsatti E, Cannizzaro R, Vitali V, Aita P, Freschi A, Galligioni E, Monfardini S, Clin Pharmacol Ther 1996 59 1 32 40 10.1016/S0009-9236(96)90021-1 8549031 (Pubitemid 26046769)
24. Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer. Egawa-Takata T, Endo H, Fujita M, Ueda Y, Miyatake T, Okuyama H, Yoshino K, Kamiura S, Enomoto T, Kimura T, et al. Cancer Sci 2010 101 10 2171 2178 10.1111/j.1349-7006.2010.01670.x 20678156
25. Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. Kuwahara D, Tsutsumi K, Kobayashi T, Hasunuma T, Nishioka K, Cancer Lett 2000 148 1 65 71 10.1016/S0304-3835(99)00315-8 10680594 (Pubitemid 30012130)
26. Dysregulation of Purine Nucleotide Biosynthesis Pathways Modulates Cisplatin Cytotoxicity in Saccharomyces cerevisiae. Kowalski D, Pendyala L, Daignan-Fornier B, Howell SB, Huang R-Y, Mol Pharmacol 2008 74 4 1092 1100 10.1124/mol.108.048256 18612078
27. The SPRY Domain-containing SOCS Box Protein 1 (SSB-1) Interacts with MET and Enhances the Hepatocyte Growth Factor-induced Erk-Elk-1-Serum Response Element Pathway. Wang D, Li Z, Messing EM, Wu G, J Biol Chem 2005 280 16 16393 16401 10.1074/jbc.M413897200 15713673 (Pubitemid 40616769)
28. FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. Al-Shahrour F, az-Uriarte R, Dopazo J, Bioinformatics 2004 20 4 578 580 10.1093/bioinformatics/btg455 14990455 (Pubitemid 38344339)
29. Quantitative Expression Profiling in Formalin-Fixed Paraffin-Embedded Samples by Affymetrix Microarrays. Abdueva D, Wing M, Schaub B, Triche T, Davicioni E, J Mol Diagn 2010 12 4 409 417 10.2353/jmoldx.2010.090155 20522636
30. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. Passing H, Bablok, J Clin Chem Clin Biochem 1983 21 11 709 720 6655447 (Pubitemid 14208512)
31. Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Shedden KA, Taylor JM, Giordano TJ, Kuick R, Misek DE, Rennert G, Schwartz DR, Gruber SB, Logsdon C, Simeone D, et al. Am J Pathol 2003 163 5 1985 1995 10.1016/S0002-9440(10)63557-2 14578198 (Pubitemid 37310029)